Keyora Antarctic Krill Oil EP-11: The MASLD Multi-Layer Response Map: From Hepatic Steatosis and TG-VLDL Dyslipidemia to MASH, Fibrosis-Risk Stratification, and Clinical Escalation

Background Metabolic dysfunction-associated steatotic liver disease, or MASLD, is frequently simplified into the concept of “fat in the liver.” This interpretation is clinically incomplete because hepatic steatosis represents only one measurable layer within a broader metabolic liver-disease spectrum. MASLD can include hepatic steatosis, metabolic dysfunction, triglyceride-rich lipoprotein abnormalities, hepatocellular stress and injury, inflammatory activity, metabolic dysfunction-associated steatohepatitis, progressive fibrosis, cirrhosis, and liver-related complications. These layers are biologically connected but clinically non-interchangeable. A reduction in circulating triglycerides does not establish a reduction in hepatic fat. A reduction in hepatic fat does not establish resolution of MASH. Improvement in ALT, AST, or GGT does not establish fibrosis regression. Likewise, improvement in an inflammatory biomarker does not establish histological disease resolution. Keyora Antarctic Krill Oil EP-11 therefore develops a disease-layer and response-object framework for interpreting where a Phospholipid Omega-3 intervention can reasonably fit within MASLD and where the intervention task must move beyond nutritional lipid management. The article integrates Keyora [The Hepatic Lipid Partitioning and Export Matrix], Keyora [The Liver-Fat Response Object], Keyora [The TG-VLDL Production-Clearance Matrix], Keyora [The Insulin-Resistance Lipid-Burden Matrix], Keyora [The Steatosis-Inflammation-Fibrosis Separation Rule], Keyora [The Fibrosis-Risk Intervention Gate], Keyora [The MASLD Multi-Layer Response Map], and Keyora [The MASLD Intervention and Response Algorithm]. Its central intervention identity is Phospholipid Omega-3, with EPA, DHA, and DPA retained within the phospholipid-rich lipid architecture. Phosphatidylcholine and total phospholipids contribute a second structural axis involving hepatocyte membranes, lipoprotein surfaces, and physiological lipid export. Choline contributes nutritional context through PC synthesis and hepatic physiology. These biological relationships support mechanism-matched nutritional interpretation. They do not establish exact finished-Keyora treatment of MASH, fibrosis, cirrhosis, or advanced liver disease. Objective The objectives of EP-11 are to: separate hepatic steatosis, hepatocellular injury, MASH, fibrosis, and cirrhosis as distinct MASLD disease and response objects; establish why improvement in one MASLD layer cannot automatically be translated into improvement in another; define hepatic steatosis as a measurable liver-fat phenotype rather than the complete disease; distinguish the visible liver-fat phenotype from the metabolic drivers sustaining hepatic triglyceride accumulation; establish Keyora [The Hepatic Lipid Partitioning and Export Matrix] as a model integrating fatty-acid inflow, de novo lipogenesis, triglyceride storage, fatty-acid oxidation, and VLDL export; integrate human tracer evidence demonstrating multiple sources of hepatic triglyceride fatty acids; distinguish adipose-derived nonesterified fatty-acid delivery from hepatic de novo lipogenesis and direct dietary fatty-acid contribution; establish why dietary fat alone cannot explain MASLD steatosis; distinguish physiological hepatic triglyceride export through VLDL from pathological VLDL overproduction; position Phospholipid Omega-3 within hepatic lipid synthesis, oxidation, triglyceride-VLDL, phospholipid-membrane, and inflammatory-lipid pathways; establish the TG-VLDL dyslipidemic phenotype as a separate response domain from liver-fat burden; distinguish a circulating TG response from a hepatic steatosis response; establish EPA and DHA as the principal Keyora fatty-acid objects with direct human triglyceride-response evidence; preserve DPA as an embedded component of the Phospholipid Omega-3 architecture without assigning unsupported independent antifibrotic efficacy; define the insulin-resistant MASLD phenotype as a multi-tissue substrate-flux disorder involving adipose tissue, liver, and skeletal muscle; integrate adipose lipolysis, hepatic substrate pressure, impaired muscle glucose disposal, and persistent DNL into the hepatic lipid-burden framework; separate improvement in lipid metabolism from direct insulin sensitization; distinguish triglycerides, fasting glucose, HbA1c, fasting insulin, HOMA-IR, and direct insulin-sensitivity measurements as different metabolic response objects; establish PC as an important structural phospholipid of hepatocyte membranes and lipoprotein architecture; establish Choline as an essential nutrient relevant to PC synthesis and hepatic physiology; distinguish PC structural necessity from exact oral-PC therapeutic efficacy; distinguish Choline nutritional adequacy or deficiency correction from MASLD treatment; establish the transition from simple steatosis toward hepatocellular stress and inflammatory liver injury; distinguish triglyceride storage from lipotoxic lipid stress; integrate mitochondrial, endoplasmic-reticulum, redox, cell-injury, and inflammatory biology without converting upstream mechanism into histological MASH diagnosis; evaluate EPA/DHA lipid-mediator and inflammatory-response biology within an evidence-bounded MASLD context; distinguish inflammatory-mediator response from liver-enzyme response and histological MASH resolution; define ALT, AST, and GGT as biochemical liver-response objects rather than direct fibrosis measurements; establish Keyora [The Steatosis-Inflammation-Fibrosis Separation Rule]; establish fibrosis as the principal liver-related prognostic gate that changes MASLD management priority; distinguish significant fibrosis, advanced fibrosis, and cirrhosis; integrate FIB-4 as a first-line fibrosis-risk filter rather than a definitive diagnosis; integrate VCTE and ELF as secondary non-invasive fibrosis-assessment tools within staged risk stratification; define when fibrosis probability changes the intervention from primarily metabolic management toward specialist-directed liver care; reconstruct exact one- and two-softgel Keyora exposure; distinguish nutritional exposure intensity from disease-stage treatment intensity; prevent twofold active-object exposure from being interpreted as twofold TG reduction, liver-fat reduction, MASH response, or fibrosis regression; establish Keyora [The MASLD Multi-Layer Response Map] so that the response object always matches the disease object; identify the residual bottleneck after a partial or domain-specific response; operationalize the full system through Keyora [The MASLD Intervention and Response Algorithm]. MASLD Is More Than Hepatic Steatosis The first governing principle is disease-layer separation. Hepatic steatosis identifies abnormal intrahepatic lipid accumulation. MASH represents a different disease layer involving inflammatory activity and hepatocellular injury. Fibrosis represents extracellular-matrix accumulation and structural remodeling. Cirrhosis represents advanced architectural distortion with different prognostic and management implications. These stages can exist within one disease continuum. They should not be used as interchangeable response endpoints. The Keyora interpretation can therefore be summarized as: Steatosis response≠ hepatocellular-injury response≠ MASH resolution≠ fibrosis regression. Keyora [The Liver-Fat Response Object] When the intervention claim concerns hepatic steatosis, the most direct response object is liver fat. Serum TG, ALT, AST, GGT, fasting glucose, HOMA-IR, and inflammatory biomarkers can provide important neighboring information. They do not directly substitute for hepatic-fat assessment. This creates a practical evidence rule: A steatosis diagnosis establishes the liver-fat disease object. A steatosis-response claim requires evidence that the liver-fat response object itself changed. Keyora [The Hepatic Lipid Partitioning and Export Matrix] Hepatic steatosis develops within a dynamic flux system rather than through simple passive fat storage. The Matrix integrates: **fatty-acid inflow de novo lipogenesis→ hepatic triglyceride pool→ storage / oxidation / VLDL export.** Liver fat increases when substrate entering or being generated within the hepatic system persistently exceeds effective metabolic disposal. This framing changes the question from: “How much dietary fat entered the liver?” to: “Which combination of substrate inflow, endogenous synthesis, oxidation, storage, and export is sustaining the hepatic triglyceride pool?” Multiple Sources of Hepatic Fatty Acids Human tracer evidence demonstrates that hepatic triglyceride fatty acids can arise from several sources simultaneously. A major source can be circulating nonesterified fatty acids generated partly through adipose lipolysis. A substantial additional contribution can arise from hepatic de novo lipogenesis. Dietary fatty acids also contribute through postprandial lipid transport and chylomicron-related pathways. The exact relative contribution varies with population and metabolic state. The scientific principle is therefore not a universal fixed percentage. It is: hepatic triglyceride has multiple converging substrate sources. Adipose-Derived NEFA Insulin normally contributes to suppression of adipose lipolysis. When adipose insulin responsiveness declines, nonesterified fatty-acid release can remain excessive relative to metabolic demand. These circulating fatty acids reach the liver and contribute substrate for: oxidation; esterification; triglyceride storage; ketogenesis; lipoprotein production. This establishes hepatic steatosis as partly an inter-organ metabolic problem rather than exclusively an intrahepatic disorder. De Novo Lipogenes